[Anemia and hemostatic abnormalities associated with multiple myeloma]

Area of Science:

• Hematology
• Oncology

Context:

• Multiple myeloma (MM) frequently presents with anemia and bleeding complications.
• Anemia in MM is attributed to marrow infiltration, chronic kidney disease, and reduced erythrocyte lifespan.

Purpose:

• To explore the therapeutic potential of erythropoietin (Epo) in managing anemia associated with multiple myeloma.
• To review hemostatic abnormalities and their management in multiple myeloma patients.

Summary:

• Erythropoietin (Epo) demonstrates efficacy in correcting anemia in some multiple myeloma patients, even without renal failure, indicating its therapeutic value.
• Despite diverse hemostatic test abnormalities in MM, severe bleeding is uncommon. Treatment primarily involves addressing the underlying malignancy, with plasma exchange as a supplemental option.

Impact:

• Highlights erythropoietin as a viable treatment for myeloma-associated anemia.
• Provides insights into managing bleeding risks in multiple myeloma, emphasizing malignancy-targeted therapy.